Roxadustat

2 papers5 findings

PubChem 11256664 ChEBI 132774 MeSH C584543

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 2 countries

Funders: European Commission and 3 more

Animals1
Cells1

Outcomes

Working memory

upin mice1

1 study

Roxadustat improves working memory in mice.
“An 8-week oral regimen of SP10 and Roxadustat significantly preserved working memory, as assessed by the Y-maze test (YMT).”
Animals8-week
Pseudohypoxia induced by iron chelators preserves working memory performance in aged mice
Scientific reports2 Mar 2026

Differentiation index

upin mouse cells1

1 study

Roxadustat increases differentiation index in mouse cells (+1.7).
“When differentiation was induced without drugs, pretreated aged SCs formed hypertrophic myotubes (differentiation index +1.7), exhibited higher ATP content (+1.54-fold)”
Cellspretreated aged SCs differentiated without drugs
The HIF-1α Pathway Regulates Satellite Cell Fate During Aging Through Histone Lactylation
Aging cell1 Feb 2026